Hot International Companies To Buy For 2015

Hot International Companies To Buy For 2015: Rigel Pharmaceuticals Inc.(RIGL)

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its product development programs include R788, which completed a phase 2 clinical trial for the treatment of rheumatoid arthritis; and is in phase 2 clinical trials for B-cell lymphoma, T-cell lymphoma, immune thrombocytopenia purpura, and certain solid tumors. The company?s product development programs also comprise R343, which is in phase 1b clinical trial for the treatment of asthma. In addition, its preclinical programs include oral JAK3 inhibitor program for research in the area of immunology/inflammation; adiponectin mimetics for the treatment of type 2 diabetes mellitus and other potential indications; and muscle atrophy program for muscle homeostasis. Further, the company is evaluating R763/AS703569 compound in its aurora kinase inhibition program targeting cancer cell proliferation. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB; Pfizer, Inc.; and Daiichi Pharmaceuticals Co., Ltd. The company was founded in 1996 and is based in South San Francisco, California.

Advisors' Opinion:

• [By Maxx Chatsko]

  Rigel Pharmaceuticals (NASDAQ: RIGL  ) was kicked in the stomach earlier this month, when AstraZeneca (NYSE: AZN  ) returned full rights for fostamatinib. The Big Pharma member decided to write off $140 million of assets attributed to the partnership rather than take the next steps in commercializing the drug for rheumatoid arthritis. Ouch. While it's a smart idea for AstraZeneca to walk away now, Rigel is in a tough spot with its top drug candidate receiving a vote of no confidence. There is a handful of companies that stand to benefit from fostamatinib's failure. In the following ! video, Fool contributor Maxx Chatsko explains what it means for investors and what the future could hold for the development-stage company.

• [By Sean Williams]

  It wasn't nearly as exciting a week for Rigel Pharmaceuticals (NASDAQ: RIGL  ) , which regained full rights to rheumatoid arthritis pill Fostamatinib from AstraZenecaon Tuesday. The pair actually reported a statistically significant ACR20 response rate at 24 weeks in two trials, but the data isn't expected to be conclusive enough to gain FDA approval. AstraZeneca, not wanting to spend any more on the program, took a $140 million charge and returned all licensing back to Rigel. With the prospect of high trial costs and a drug which did well, but perhaps not well enough to compete with competition already on the market, Rigel is now in a tough position and is worth avoiding at all costs.

• [By Keith Speights]

  Pain-medication pain
  Rigel Pharmaceuticals (NASDAQ: RIGL  ) experienced pain this week, resulting from its drug intended to help rheumatoid arthritis patients suffer less pain. Shares fell almost 23%.

• [By Max Macaluso, Ph.D.]

  Early Tuesday morning, Rigel Pharmaceuticals (NASDAQ: RIGL  ) and its now-ex-partner, AstraZeneca (NYSE: AZN  ) , reported late-stage clinical trial results for the experimental rheumatoid arthritis drug Fostamatinib. In the following video, health-care analyst Max Macaluso discusses why Rigel dropped 18% after the news was released and the risks that lie ahead for Rigel Pharmaceuticals.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/hot-international-companies-to-buy-for-2015-4.html